Ipamorelin vs CJC-1295: How Do They Differ?

Structural Architecture and Sequence Composition

Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, containing 5 amino acids and a molar mass of 711.85 Da. The peptide incorporates the non-standard residue α-aminoisobutyric acid (Aib), two D-amino acids (D-2-naphthylalanine and D-phenylalanine), and C-terminal amidation. This compact architecture was designed through structure-activity relationship studies to identify the minimal sequence required for growth-hormone-releasing-peptide receptor recognition. The small size enables efficient chemical synthesis and contributes to the peptide's biochemical properties.Review · PMID 18193177

CJC-1295 is a 30-amino-acid peptide derived from growth-hormone-releasing hormone (GHRH) with a synthetic modification: a lyophilized dipeptide extension added to the C-terminus. This modification—distinct from natural post-translational modifications—was engineered during chemical synthesis to alter peptide biophysical properties. The full-length sequence corresponds to GHRH(1-29) with the dipeptide extension, producing a 30-residue triacontapeptide. Unlike ipamorelin's minimalist design emphasizing compact sequence, CJC-1295's extended architecture maintains structural homology with the natural hormone GHRH while incorporating the stability-related modification.Review · PMID 10429879In vitro · PMID 30136411

The compositional difference between the peptides reflects distinct design strategies in growth-hormone-releasing peptide development. Ipamorelin represents sequence minimization: containing only 5 amino acids selected through systematic variation for optimal receptor binding in a compact framework. CJC-1295 represents structure-guided modification: incorporating the known GHRH sequence with engineered chemical changes to optimize pharmacological properties. These contrasting approaches—minimization versus modification of a natural sequence—represent two paradigms in synthetic peptide drug design.In vitro · PMID 41074841Review · PMID 10429879

Receptor Mechanisms and Signaling Characterization

Ipamorelin is characterized as a growth-hormone-releasing-peptide receptor (GHRP-R) agonist through in-vitro biochemical assays. The pentapeptide binds to GHRP receptors via specific molecular interactions in biophysical binding assays measured by surface plasmon resonance, fluorescence spectroscopy, and cell-free receptor-ligand measurements. Cultured cell studies measure receptor activation through intracellular calcium mobilization, kinase phosphorylation (ERK, Akt), and gene-expression changes measured by quantitative PCR. These characterized mechanisms describe how the compact peptide achieves specific receptor recognition.In vitro · PMID 35836065In vitro · PMID 41074841

CJC-1295 is characterized as a growth-hormone-releasing-hormone (GHRH) receptor agonist acting through the same signal transduction pathway as natural GHRH. In-vitro cell-based assays measuring CJC-1295-induced GHRH receptor activation employ the same techniques as ipamorelin studies: calcium imaging, phosphoprotein detection, and gene-expression analysis. Both peptides ultimately activate the same downstream signaling cascades through their respective receptor agonism, though the mechanisms of receptor engagement differ based on their distinct chemical structures.In vitro · PMID 33060564Review · PMID 10429879

A fundamental distinction in research characterization exists: ipamorelin represents direct GHRP receptor agonism through non-natural peptide design, while CJC-1295 represents GHRH receptor agonism through a natural-sequence-derived peptide with synthetic modifications. The signaling readouts measured in cultured cells are similar—both activate growth-hormone-releasing pathways—but the molecular recognition mechanisms and receptor selectivity profiles reflect their distinct chemical architectures. The GHRP receptor and GHRH receptor, while sharing common downstream signaling cascades (calcium mobilization, kinase activation, gene expression), represent distinct cellular receptors with different ligand-binding specificity. No published direct comparative study in identical biophysical or cell-based systems has measured relative receptor affinity or signaling potency for ipamorelin and CJC-1295 in parallel experiments.In vitro · PMID 41074841In vitro · PMID 33060564

Stability Characterization and Biochemical Persistence

Ipamorelin is characterized through in-vitro degradation assays examining its resistance to proteolytic digestion. The inclusion of D-amino acids and the non-standard Aib residue confers protection against enzymatic cleavage by proteases that recognize L-amino-acid stereochemistry. Liquid chromatography-mass spectrometry tracking of peptide integrity over time in buffer containing protease cocktails (trypsin, chymotrypsin) demonstrates significant stability compared to all-L-amino-acid analogs. These studies characterize the peptide's biochemical durability in defined in-vitro conditions.In vitro · PMID 35836065In vitro · PMID 41074841

CJC-1295 is characterized in in-vitro biochemical assays examining the activity of the synthetic C-terminal modification on peptide stability in aqueous solutions. High-performance liquid chromatography and mass spectrometry tracking measures peptide persistence at physiological pH and temperature. Enzymatic-degradation assays expose the peptide to protease solutions and measure intact peptide detection over time by analytical chromatography. The synthetic dipeptide extension, while conferring greater stability compared to unmodified GHRH, represents a different stabilization mechanism than ipamorelin's non-natural amino acids: chemical modification rather than stereochemical modification.In vitro · PMID 34665524In vitro · PMID 30136411

The stability mechanisms of the two peptides reflect their distinct chemical compositions. Ipamorelin's protease resistance arises from D-amino acid incorporation and the non-standard Aib residue—features unrecognized by standard proteolytic enzymes. CJC-1295's greater stability derives from the synthetic dipeptide extension modifying the peptide's susceptibility to enzymatic cleavage at specific recognition sites. Both approaches achieve proteolytic resistance through different chemical strategies, resulting in peptides with measurably distinct degradation kinetics in in-vitro biochemical assays.In vitro · PMID 35836065In vitro · PMID 34665524

Analytical Characterization and Identification Methods

Both ipamorelin and CJC-1295 are characterized through standard peptide analytical methods including high-performance liquid chromatography (HPLC) and mass spectrometry. HPLC with reversed-phase separation provides purity assessment and detection of synthetic variants. Mass spectrometry determines precise molar mass and confirms sequence identity. For ipamorelin, special attention focuses on confirming the presence of D-amino acids and the non-standard Aib residue. For CJC-1295, analytical verification confirms the synthetic dipeptide modification is intact and properly positioned.In vitro · PMID 35836065In vitro · PMID 34665524

Ipamorelin requires specialized analytical methods to confirm its non-natural amino-acid composition. Tandem mass spectrometry fragmentation enables identification of each residue through characteristic fragment patterns. Chiral analysis or two-dimensional peptide analysis distinguishes D-amino acids from their L-amino-acid counterparts. Nuclear magnetic resonance spectroscopy provides conformational information and validates structural assignments. These comprehensive analytical approaches establish the complete structural identity of the synthetic pentapeptide.In vitro · PMID 41074841In vitro · PMID 35836065

CJC-1295 characterization emphasizes validation of the synthetic modification—confirming that the designed C-terminal dipeptide extension is present and intact. Mass spectrometry must distinguish the modified peptide from unmodified GHRH(1-29) and identify any partially modified variants. Amino-acid compositional analysis validates the complete 30-residue sequence. These analytical methods verify that the engineered stability modification is correctly incorporated during chemical synthesis.In vitro · PMID 34665524

The studies at a glance

Comparative characterization of ipamorelin and CJC-1295 through in-vitro biochemical methods

Frequently asked questions